It is primarily used in combination multidrug therapies against canine lymphoma, transitional cell carcinoma and in combination with toceranib, nitrosourea and prednisolone against mast cell tumors, with variable results.
Recommended dose rate in dogs is 2 - 4 mg/m2 every 7 - 14 days, given intravenously. Regular monitoring of CBC is recommended.
- Arnold EJ et al (2011) Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 25(6):1385-1390
- Rassnick KM et al (2010) A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Vet Comp Oncol 8(2):138-152
- Robat C et al (2012) Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study. Vet Comp Oncol. 2012 Sep;10(3):174-83
- O'Connell K & Thomson M (2013) Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases. Vet Comp Oncol 11(1):51-62